164 related articles for article (PubMed ID: 21822767)
1. Development and evaluation of a prototype of a novel clotting time test to monitor enoxaparin.
Gulati A; Faed JM; Isbister GK; Duffull SB
Pharm Res; 2012 Jan; 29(1):225-35. PubMed ID: 21822767
[TBL] [Abstract][Full Text] [Related]
2. An Evaluation of a Factor Xa-Based Clotting Time Test for Enoxaparin: A Proof-of-Concept Study.
Ng DPJ; Duffull SB; Faed JM; Isbister GK; Gulati A
Clin Appl Thromb Hemost; 2018 May; 24(4):669-676. PubMed ID: 28731370
[TBL] [Abstract][Full Text] [Related]
3. Application of Adaptive DP-optimality to Design a Pilot Study for a Clotting Time Test for Enoxaparin.
Gulati A; Faed JM; Isbister GK; Duffull SB
Pharm Res; 2015 Oct; 32(10):3391-402. PubMed ID: 26129765
[TBL] [Abstract][Full Text] [Related]
4. Monitoring effects of direct FXa-inhibitors with a new one-step prothrombinase-induced clotting time (PiCT) assay: comparative in vitro investigation with heparin, enoxaparin, fondaparinux and DX 9065a.
Graff J; Picard-Willems B; Harder S
Int J Clin Pharmacol Ther; 2007 Apr; 45(4):237-43. PubMed ID: 17474542
[TBL] [Abstract][Full Text] [Related]
5. Enhanced anticoagulant activity of enoxaparin in patients with ESRD as measured by thrombin generation time.
Brophy DF; Martin EJ; Gehr TW; Carr ME
Am J Kidney Dis; 2004 Aug; 44(2):270-7. PubMed ID: 15264185
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the anticoagulant intensities of fondaparinux and enoxaparin in the Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial.
Anderson JA; Hirsh J; Yusuf S; Johnston M; Afzal R; Mehta SR; Fox KA; Budaj A; Eikelboom JW
J Thromb Haemost; 2010 Feb; 8(2):243-9. PubMed ID: 19943881
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of Enoxaparin Dosing as a Risk Factor for Bleeding in Lung Transplant Recipients.
Sofjan AK; Iuppa JA; Bain KB; Deal EN; Witt CA; Hachem RR; Yusen RD
Ann Pharmacother; 2016 Oct; 50(10):824-31. PubMed ID: 27363845
[TBL] [Abstract][Full Text] [Related]
8. Retrospective evaluation of antithrombin III supplementation in neonates and infants receiving enoxaparin for treatment of thrombosis.
Corder A; Held K; Oschman A
Pediatr Blood Cancer; 2014 Jun; 61(6):1063-7. PubMed ID: 24375987
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of enoxaparin in early stage of paediatric liver transplantation.
Oualha M; Chardot C; Debray D; Lesage F; Harroche A; Renolleau S; Treluyer JM; Urien S
Br J Clin Pharmacol; 2018 Jun; 84(6):1206-1214. PubMed ID: 29423936
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a novel point-of-care enoxaparin monitor with central laboratory anti-Xa levels.
Saw J; Kereiakes DJ; Mahaffey KW; Applegate RJ; Braden GA; Brent BN; Brodie BR; Groce JB; Levine GN; Leya F; Moliterno DJ
Thromb Res; 2003; 112(5-6):301-6. PubMed ID: 15041274
[TBL] [Abstract][Full Text] [Related]
11. The use of a HEMOCHRON JR. HEMONOX point of care test in monitoring the anticoagulant effects of enoxaparin during interventional coronary procedures.
El Rouby S; Cohen M; Gonzales A; Hoppensteadt D; Lee T; Zucker ML; Khalid K; Laduca FM; Fareed J
J Thromb Thrombolysis; 2006 Apr; 21(2):137-45. PubMed ID: 16622609
[TBL] [Abstract][Full Text] [Related]
12. Retrospective comparison of two enoxaparin dosing and monitoring protocols at a pediatric hospital.
Wolsey A; Wilcox RA; Olson JA; Boehme S; Anderson CR
Am J Health Syst Pharm; 2019 May; 76(11):815-819. PubMed ID: 31361813
[TBL] [Abstract][Full Text] [Related]
13. Determination of enoxaparin with rotational thrombelastometry using the prothrombinase-induced clotting time reagent.
Schaden E; Schober A; Hacker S; Spiss C; Chiari A; Kozek-Langenecker S
Blood Coagul Fibrinolysis; 2010 Apr; 21(3):256-61. PubMed ID: 20087172
[TBL] [Abstract][Full Text] [Related]
14. Comparison between activated clotting time and anti-activated factor X activity for the monitoring of unfractionated heparin therapy in patients with aortic aneurysm undergoing an endovascular procedure.
Dieplinger B; Egger M; Luft C; Hinterreiter F; Pernerstorfer T; Haltmayer M; Mueller T
J Vasc Surg; 2018 Aug; 68(2):400-407. PubMed ID: 29571622
[TBL] [Abstract][Full Text] [Related]
15. Prospective comparison of three enoxaparin dosing regimens to achieve target anti-factor Xa levels in hospitalized, medically ill patients with extreme obesity.
Freeman A; Horner T; Pendleton RC; Rondina MT
Am J Hematol; 2012 Jul; 87(7):740-3. PubMed ID: 22565589
[TBL] [Abstract][Full Text] [Related]
16. Rivaroxaban and apixaban are less effective than enoxaparin for the prevention of catheter-induced clotting in vitro.
Guan Z; Wang R; Hussain RH; Fredenburgh JC; Jaffer IH; Weitz JI
J Thromb Haemost; 2023 Jan; 21(1):76-82. PubMed ID: 36695399
[TBL] [Abstract][Full Text] [Related]
17. Individualized dosing of enoxaparin in a morbidly obese patient by monitoring the anti-factor Xa.
Mazhar F; Ahmed Y
Int J Clin Pharmacol Ther; 2017 Feb; 55(2):169-170. PubMed ID: 27936527
[No Abstract] [Full Text] [Related]
18. Trauma patients with lower extremity and pelvic fractures: Should anti-factor Xa trough level guide prophylactic enoxaparin dose?
Dhillon NK; Smith EJT; Gillette E; Mason R; Barmparas G; Gewertz BL; Ley EJ
Int J Surg; 2018 Mar; 51():128-132. PubMed ID: 29367044
[TBL] [Abstract][Full Text] [Related]
19. Thromboelastography as a perioperative measure of anticoagulation resulting from low molecular weight heparin: a comparison with anti-Xa concentrations.
Klein SM; Slaughter TF; Vail PT; Ginsberg B; El-Moalem HE; Alexander R; D'Ercole F; Greengrass RA; Perumal TT; Welsby I; Gan TJ
Anesth Analg; 2000 Nov; 91(5):1091-5. PubMed ID: 11049889
[TBL] [Abstract][Full Text] [Related]
20. Are activated clotting times helpful in the management of anticoagulation with subcutaneous low-molecular-weight heparin?
Henry TD; Satran D; Knox LL; Iacarella CL; Laxson DD; Antman EM
Am Heart J; 2001 Oct; 142(4):590-3. PubMed ID: 11579347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
